Camp4 Secures $100 Million Series B Financing To Accelerate Expansion Of Its Novel Regulatory Rna-Targeting Platform And Advance Lead Programs Into The Clinic
Camp4 Secures $100 Million Series B Financing To Accelerate Expansion Of Its Novel Regulatory Rna-Targeting Platform And Advance Lead Programs Into The Clinic
07/20/22, 10:02 AM
Location
cambridgeMoney raised
$100 million
Industry
science and engineering
biotechnology
Round Type
series b
CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, today announced the closing of a $100 million Series B round to advance the company’s lead regRNA programs and accelerate the expansion of the company’s regRNA Actuating Platform. Enavate Sciences, a portfolio company created by Patient Square Capital, led the round. Additional investors in the Series B financing include a large national managed care organization and the Gaingels, an LGBTQIA+/Allies investment syndicate supporting diversity in venture capital, along with other unnamed investors. Existing investors 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group, and others also joined the round.
Company Info
Location
one kendall square
cambridge, maryland, united states
Additional Info
At CAMP4, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our RNA Actuating Platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Learn more about us at www.CAMP4tx.com and follow us @CAMP4tx.